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TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING IN
PATIENTS WITH ACUTE MYELOID LEUKAEMIA IN SWEDEN
Aschan, J.1; Ringde´n, O.1; Wahlin, A.2; Wernstedt, P.3; Brune, M.3 1.
Centre for Allogeneic Stemcell Transplantation, Karolinska University
Hospital Huddinge, Stockholm, Sweden; 2. Department of Hematology,
Norrlands University Hospital, Umeå, Sweden; 3. Department of He-
matology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Thirty-seven patients, median age 58 yrs (8–69), with AML
undergoing allogeneic stem cell transplantation (SCT) after re-
duced intensity conditioning (RIC) at three Swedish SCT centers
were analyzed retrospectively. All except six patients received RIC
due to high age or co-morbidity. Twenty-three patients were
transplanted in ﬁrst remission and 14 with more advanced disease.
Donors were siblings (n22) or matched unrelated donors (MUD,
n15). Conditioning was ﬂudarabine  busulfan 	 anti-thymo-
cyte globulin (n32), ﬂudarabine  treosulfan (n3) or ﬂudara-
bine  2 Gy total body irradiation (n2). As stem cell source bone
marrow was used in six patients and peripheral blood stem cells in
31. All patients engrafted. At a median follow-up of 15 months
(3–63) acute graft-versus-host disease (GVHD) grade 0/I/II/III/IV
developed in 22/7/5/0/1 recipients, respectively. Limited chronic
GVHD was seen in ﬁve and extensive in seven patients among 33
patients at risk. Donor lymphocyte infusions were given to 16
patients due to mixed chimerism, minimal residual disease or
relapse. In total 15 patients relapsed and 12 of them died. Only one
patient died from a transplant related cause, acute GVHD. Kaplan-
Meier probability for survival at 1 yr is 79% and for leukaemia-free
survival (LFS) 68%. Among 23 patients, age 53 yrs (8–69) trans-
planted in ﬁrst remission with 16 sibling donors and seven MUD,
eight relapsed (35%) and ﬁve of them died. There was no trans-
plant-related mortality (TRM) among patients in ﬁrst remission.
Kaplan-Meier probability for survival and LFS at 1 yr is 86% and
72%, respectively for patients receiving transplantation in ﬁrst
remission. Reduced intensity conditioning with a ﬂudarabine con-
taining regimen and transplantation with a sibling or MUD gives
a low TRM even in older patients with AML. Survival is encour-
aging but leukemia relapse remains a major problem. Randomized
or controlled prospective trials comparing RIC with conventional
conditioning for younger patients and trials comparing RIC to
chemotherapy for elderly patients are urgently warranted.
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ABSENCE OF PRIOR INFECTIONS IS STRONGEST PREDICTOR FOR SUR-
VIVAL AFTER ALTERNATE DONOR HEMATOPOIETIC CELL TRANSPLAN-
TATION IN PATIENTS WITH FANCONI ANEMIA
MacMillan, M.L.1; Auerbach, A.D.2; Champagne, M.A.3; DeFor,
T.E.1; Slungaard, A.1; Weisdorf, D.J.1; Wagner, J.E.1 1. University of
Minnesota, Minneapolis, MN; 2. The Rockefeller University, New York,
NY; 3. Hopital Ste-Justine, Montreal, PQ, Canada.
Alternate donor hematopoietic cell transplantation (HCT) in
patients with Fanconi anemia (FA) has been limited by excessive
rates of graft failure (GF). In an attempt to improve results, a phase
I-II prospective trial was conducted in which ﬂudarabine (FLU,
140 mg/m2) was added to the standard regimen of cyclophospha-
mide (CY, 40 mg/kg), total body irradiation (TBI, 450 cGy) and
ATG (150 mg/kg). Between April 1999 and August 2003, 45
patients with FA (AA [n29], early MDS [n13], RAEBt/AML
[n3]) underwent T cell depleted bone marrow (BM; n38) or
umbilical cord blood transplantation (UCB; n7) from alternate
donors (HLA-mismatched related or unrelated), and were followed
for a median of 2 years (range, 1–5.3 years). Median age was 10
years (range, 1.9–33.5 years). Median BM median CD34 cells/kg
and CD3 cells/kg infused was 2.23  108 and 1  105. Median
UCB CD34 cells/kg and CD3 cells/kg infused was 3.3  105
and 1.7  106. Probability of primary neutrophil engraftment was
98% (95% CI 93–100%), a superior outcome compared to that
observed with our previous CY/TBI/ATG regimen (63% [95%
CI, 42–82%]; p
.01). Neutrophil engraftment was achieved in
15/15 patients with somatic mosaicism, a potential risk factor for
GF. Median time to neutrophil engraftment was 11 days (range,
9–35 days) in BM recipients and 14 days (range 9–36 days) in UCB
recipients. Two patients died from RRT. Probability of grade
II-IV acute GVHD was 18% (95% CI, 7–29%) and chronic
GVHD 13% (95% CI 3–23%). Probability of 1 year survival was
55% (95% CI 41–70%). In univariate analysis, high risk patient
characteristics associated with poor survival are age 18 years,
presence of RAEBt/AML, and history of major infection (fungal
infection or gram negative sepsis) prior to HCT. In multivariate
analysis, patients with a history of severe infections prior to HCT
had a 3.2 fold increased risk of mortality (95% CI 1.3–8.0; P.01).
In summary, addition of FLU to CY, TBI and ATG is associated
with superior engraftment in FA patients undergoing alternate
donor HCT. Rates of GVHD are low which may reduce the risk
of late malignancies. On the basis of these results, FLU based
preparative therapies should be considered part of the standard of
care in FA patients undergoing HCT. In addition, patients should
be transplanted earlier, before the development of serious infec-
tions.
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INFLUENCE OF KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR)
MATCHING ON ACHIEVEMENT OF T-CELL (CD3) COMPLETE DONOR
CHIMERISM (CDC) IN RELATED DONOR NONMYELOABLATIVE ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (NMHSCT)
Sobecks, R.; Ball, E.; Theil, K.; Brown, S., Rybicki, L.; Maciejewski, J.;
Kalaycio, M.; Pohlman, B.; Baker, J.; Bernhard, L.; Cherni, K.; Bolwell,
B. Cleveland Clinic Foundation, Cleveland, OH.
The interaction of KIRs with target cell HLA class I molecules
regulates the reactivity of NK cells and some T cell populations.
KIR interactions have been suggested to inﬂuence outcomes of
haploidentical and HLA-identical allogeneic HSCT. However, in
NMHSCT when both donor and recipient hematopoiesis may
coexist the effect of KIR interactions on outcomes is not well
known. We analyzed 31 patients undergoing related donor NMH-
SCT at our institution from 5/00–11/03. Diagnoses included 4
AML, 1 CLL, 4 CML, 2 Hodgkin’s lymphoma, 4 MDS, 2 myelo-
ﬁbrosis, 5 myeloma, 5 NHL, and 4 renal cell carcinoma. All
patients received a preparative regimen of ﬂudarabine 30 mg/m2/d
on days5,4,3, and total body irradiation 200 cGy on day1.
The median age was 51 yrs (range, 21–63 yrs). The median
CD34 and CD3 cell doses infused were 6.64  106/kg and
3.92  108/kg, respectively. CDC was deﬁned as achievement of
95% DNA of donor origin in the T-cell (CD3) enriched frac-
tions. Twenty-three (74%) of patients achieved CDC and 15
(65%) of these had a KIR mismatch, suggesting that KIR matching
per se did not correlate with CDC achievement. However, when
patient inhibitory KIR and donor ligand matches were considered
an association with CDC was observed. HLA KIR ligands were
categorized as: 1) HLA-Cw groups C1 ( or ); 2) C2 ( or );
3) HLA-Bw4 ( or ); and 4) HLA-A3 or A11 ( or ) (as
reviewed by Farag et al in Blood 100:1935, 2002). Patient KIR
genotype and donor HLA KIR ligands were used to generate an
inhibitory KIR score from 1 to 4 for the potential number of
inhibitory KIRs engaged. When the patients were analyzed 4 had
a score of 1, 16 had a score of 2, 10 had a score of 3 and 1 had a
score of 4. The Kaplan-Meier method was used to estimate the
achievement of CDC. As compared with those patients with a
score of1 the patients with a score of 1 were less likely to achieve
CDC (p0.05). Thus, patients with lower inhibitory KIR scores
may have more active anti-donor effector cells (NK cells and T cell
subsets) that may reduce donor cell chimerism. Conversely, those
with higher inhibitory KIR scores may have less active populations
and be more likely to achieve CDC. However, further investiga-
tion of larger patient populations is clearly warranted.
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REGIMEN RELATED TOXICITY AFTER THIOTEPA, CYCLOPHOSPHAMIDE
AND INTRAVENOUS BUSULFAN AS CONDITIONING FOR ALLOGENEIC
STEM CELL TRANSPLANTATION
Sanz, J.; Sanz, G.F.; Moscardo´, F.; Cupelli, L.; Montesinos, P.; Puig,
N.; Lorenzo, I.; Benlloch, L.; Jarque, I.; de la Rubia, J.; Martı´nez, J.;
Martı´n, G.; Sanz, M.A. Hospital Universitario La Fe, Valencia, Spain.
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Objectives: To evaluate veno-occlusive disease of the liver
(VOD) and non-hepatic regimen related toxicity (RRT) in patients
receiving allogeneic stem cell transplantation (allo-SCT) after con-
ditioning with BUCY plus thiotepa, using an intravenous (IV)
formulation of busulfan. Patients and Methods: Twenty-six adult
patients (20 men and 6 women; median age 32 years) underwent
allo-SCT between 2002 and 2004 after conditioning with thiotepa
(10 mg/kg), CY (120 mg/kg) and IV BU (9.6 mg/kg). Fourteen
patients received anti-thymocyte globulin (ATG). Diagnoses were
acute leukemia or myelodysplastic syndrome (20 patients), chronic
myeloid leukemia (3 patients) and other diseases (3 patients). Ten
patients received grafts from HLA-identical siblings and 16 from
alternative donors (cord blood in 12 cases). GVHD prophylaxis
consisted of cyclosporin A (CsA) and prednisone in 16 cases, CsA
and methotrexate in 9 and CsA alone in 1. VOD and non-hepatic
RRT were assessed according to Baltimore and Bearman criteria,
respectively. Results were compared to 53 historical controls who
underwent allo-SCT between 1997 and 2004 using the same con-
ditioning regimen but giving oral BU (12 mg/kg) instead of IV BU.
Results: Four of 26 patients (15%) developed VOD which was
resolved before day 100 after transplant in all cases. Severe VOD
was not observed. Signiﬁcant increases (more than 2 fold) in AST
and total bilirubin levels were observed in 19 patients (73%). The
median maximum levels of AST and total bilirubin were 72 U/L
and 2 mg/dL, respectively. Sixteen patients (62%) developed non-
hepatic RRT that was greater than grade 1 in 13 cases (50%). The
VOD rate was not signiﬁcantly different when comparing patients
receiving IV BU and oral BU (15% vs. 6%; P  0.2). However,
non-hepatic RRT was more frequent among patients receiving oral
BU (92% vs. 61%; P .002), with a higher toxicity rate of grade 2 or
more (76% vs. 50%; P  0.02). No differences were found between
the two groups regarding the underlying disease, type of transplant,
age of patients and use of ATG. MTX was more commonly used in
patients receiving IV BU (35% vs. 15%; P  0.05). Conclusions:
The use of IV BU seems to reduce non-hepatic toxicity after condi-
tioning with BUCY plus thiotepa for allo-SCT.
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LESS TRANSPLANT-RELATED MORTALITY WITH VARIABLE INTENSITY
CONDITIONING THAN NON-MYELOABLATIVE CONDITIONING IN UNRE-
LATED AND RELATED ADULT ALLOGENEIC TRANSPLANT RECIPIENTS
Bigelow, C.L.; Elkins, S.; Hardy, C.L.; Files, J.C. University of Mis-
sissippi Medical Center, Jackson, MS.
For the past four years, our adult allogeneic transplant program
has employed two alternative approaches to standard recipient
conditioning, the use of non-myeloablative “mini” conditioning
and variable intensity conditioning. We now report a retrospective
comparison of relapse, day 100 and one-year survival, engraft-
ment and grades I-II and III-IV acute GVHD in unrelated as well
as related recipients in these two preparative regimen groups.
Patients with a variety of malignancies were not randomized to
receive either non-myeloablative (Group 1) or variable intensity
(Group 2) conditioning. Twenty patients with a median age of 49
(range 27–64, Group 1) and 18 patients also with a median age of
49 (range 24–58, Group 2) received either marrow or peripheral
blood stem cells, usually with a 6/6 match grade. One recipient in
Group 2 received a cord blood transplant (4/6 match). Group 1
regimen consisted of four protocols: ﬂudarabine 30 mg/m2  3 d
and TBI 200 cGY; ﬂudarabine  6 d, busulfan 4 mg/kg  2 d and
ATG 40 mg/kg 4 d; ﬂudarabine 5 d and cyclophosphamide 60
mg/kg  2 d; ﬂudarabine, cyclophosphamide, ATG. Group 2
regimen consisted of Campath 20 mg/d either 5 or 3 days, ﬂudara-
bine  5 d and melphalan 140 mg/m2  1 d. GVHD prophylaxis
was the same in both groups (standard dose cyclosporine or ta-
crolimus and MMF.) All patients received an adequate CD34 cell
dose and none of the products was manipulated. Relapse rate was
16% in Group 1 and 33% in Group 2. Day 100 survival and
one-year survival were 55% and 25%, respectively, in Group 1 vs
69% and 42% in Group 2. Only one patient in Group 2 had acute
GVHD, grades I-II; none had grades III-IV. However, in Group 1,
6 patients had grades I-II and 7 had grades III-IV (39%). Graft
failure occurred in four patients in Group 1, while no patients in
Group 2 experienced it. We conclude, ﬁrst, that in our program
the application of variable intensity conditioning has been quite
successful in unrelated transplant recipients, as well as in related.
Second, signiﬁcant treatment related mortality in the form of graft
failure and acute GVHD occurred less frequently in recipients who
received this conditioning than in those receiving non-myeloabla-
tive conditioning. This regimen requires some modiﬁcation to
enhance its tumoricidal properties; however, its treatment-related
toxicity is minimal and allows us to offer this therapy to patients
with co-morbid conditions and older age.
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REPLACEMENT DONOR PROGRAM: MORE THAN PROTECTING STEM
CELL DONORS FROM MULTIPLE DONATIONS FOR DIFFERENT PA-
TIENTS
Baier, D.M.; Gawellek, A.; Rutt, C. DKMS Deutsche Knochenmark-
spenderdatei gGmbH, Tuebingen, Germany.
Goal of DKMS’ Replacement Donor Program is to provide an
alternative donor for search centers in case that a donor has
completed a stem cell donation and is reserved for potential further
donations for the same patient for 2 years. First intention is to
provide a donor as long as possible for “his” patient afterwards the
2 year suspension. This would enable us to provide second or
further stem cell donations if required for the one patient. Second
intention is to protect the donor from requests for multiple pa-
tients. It could be observed several times that post-donation donors
were of increased interest for search centers and were requested for
conﬁrmatory typing (CT) several times. Providing alternative do-
nors would take off the burden from a single donor. Third inten-
tion is to ﬁll up the gap in HLA-phenotypes when a donor is
suspended from further donations for 2 years after donation and to
increase the number of high resolution typed donors at DKMS.
We think that donor centers like the DKMS have the responsibil-
ity to protect their donors from excessive demand by search cen-
ters. Forth intention is to provide an alternative donor for donors
in actual workups in case that the donor in workup is unavailable
for unpredictable reasons. As the search for the Replacement Do-
nor starts with initiation of the workup it is very important that the
full HLA-phenotype of the patient is available as early as possible.
We perform up to 100 DRB1* intermediate resolution or up to 5
DRB*/DQB1* high resolution typings with IDMs (CMV) on our
own behalf for each donor at initiation of workup per own search
to ﬁnd a Replacement Donor. Own searches are repeated two
times. Until October 2004, over 87000 HLA-DRB1* typings on
intermediate and 8600 high resolution typings of HLA-DRB* and
HLA-DQB1* were performed to provide Replacement Donors for
more than 3200 donors. Replacement Donors could be found for
994 donors to date. We could not only ﬁnd Replacement Donors
but also improved the quality of our database. This is shown by the
fact that over 3900 further requests (high resolution typing or
conﬁrmatory typing) and 340 workups could be observed out of the
over 95000 “prospective” typings. Only a few (7) stem cell donors
donated again for another patient since start of the project. In 5
cases a Replacement Donor could replace an unavailable donor
while the workup was still in process. (DKMS performed over 3900
donations since start of this project in 2001.)
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LONG-TERM OUTCOME AFTER MARROW TRANSPLANTATION FROM
HLA-IDENTICAL SIBLING DONORS FOR ACQUIRED APLASTIC ANAEMIA
USING CYCLOPHOSPHAMIDE AND IN-VIVO ANTI-CD52 MONOCLONAL
ANTIBODIES
Gupta, V.1; Ball, S.E.1; Yi, Q.-L.2; Sage, D.3; McCann, S.R.4; Lawler,
M.4; Ortin, M.1; Freires, M.1; Hale, G.5; Waldmann, H.5; Gordon-
Smith, E.C.1; Marsh, J.C.W.1 1. Department of Haematology, St.
George’s Hospital and Medical School, London, United Kingdom; 2.
Department of Biostatistics, Princess Margaret Hospital, Toronto, Can-
ada; 3. National Blood Service, London, United Kingdom; 4. John
Durkan Leukemia Research Laboratory, St. James Hospital, Dublin,
Ireland; 5. Sir William Dunn School of Pathology, Oxford University,
Oxford, United Kingdom.
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